Earnings call: Philips reports progress amid Respironics recall resolution

As mentioned in our previous earnings call, we anticipate sales growth to be back-end loaded in 2024 due to the tougher comparison base in the first half of the year resulting mainly from the strong China performance in the first half of 2023 and the anticorruption measures ongoing in the first half of this year. So let's first get through this year and then at the end of the year, we will decide on how we will deal with our dividend for next year. Do you still expect margins to be down in the second quarter? And then I guess if the improvement in the back half of the year, particularly pronounced in Q3 versus Q4, just because last year was such an unusual year, if you could help us understand that. So we will make further progress into the range this year, and then progress in the range next year as well. Just one sort of regulation to that, Roy, when you look at the P&L for the last few years, and I suspect even the next couple of years, there's obviously a lot of adjustments and cash charges and things like that. China, bulk of the business is in D&T. So therefore, the impact on D&T is slightly higher than CC. And for the U.S. In terms of sales, I think the main reason there is the comps compared to last year because we went out of the blocks with a huge growth last year in Q1 and that's what makes it difficult in terms of the comps for this year. So you seem to be pretty pleased with the momentum in the U.S. And I think at the beginning of the year, you said that, I mean orders will be strong in the U.S. because like financing conditions would become a bit more easy for the year with interest rate cuts.